Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	2,078,248	3,089,689
Depreciation	827	1,248
Research and development (including stock-based compensation (Note 7))	748,545	1,123,836
Total operating expenses	2,827,620	4,214,773
Loss from operations	(2,827,620)	(4,214,773)
Other (income) expense:
Gain on extinguishment of liabilities		(122,423)
Forgiveness of debt	(34,800)
Other income		(6,000)
Interest expense	657,945	466,891
Total other expense	623,145	338,468
Net loss	(3,450,765)	(4,553,241)
Net loss attributable to the noncontrolling interest	2,785	7,506
Net loss applicable to Bion's common stockholders	$ (3,447,980)	$ (4,545,735)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.10)	$ (0.16)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	33,068,832	29,031,106